MCL1 and neoplasm: Importantly, combinatorial therapy caused significant reduction in tumor burden compared with VEN or AZD5991 single agent cohorts, indicating that MCL-1 inhibition with AZD5991 restored VEN sensitivity in MOLM-13 NRAS-G12D CLDX (Fig. 5e, f, g, Supplementary Fig. 5f).